Upsher-Smith Laboratories, Inc. received approval from the FDA for the marketing of Divigel(R) (estradiol gel) 0.1 %. The drug contains the lowest approved dose of estradiol and is indicated for the treatment of moderate to severe hot flashes caused by hormonal decline in menopause.

Preliminary studies on Divigel(R) showed that women using it experienced a low incidence of side effects and a decrease in severity of hot flashes within just two weeks.

Divigel(R) supports the North American Menopause Society (NAMS) guidelines that indicate that estrogen therapy should be used at the lowest effective dose for the shortest amount of time. The estrogen in Divigel ® is, in comparison to the older estrogen treatments using the pregnant mares, derived from plant sources and is identical to the primary estrogen produced by a woman's ovaries before the hormonal decline started.

Divigel(R) is in a form of quick-drying gel that is odorless when dry. One packet of gel is applied to the thigh where it is directly absorbed into the bloodstream without having to pass through the liver. Divigel(R) can be taken in three different strengths (0.25 mg estradiol/day, 0.5 mg estradiol/day and 1.0 mg estradiol/day) and individualized for each woman.
The President of the Upsher-Smith Laboratories, Inc. reported that the product will be made available commercially in July 2007.